Pazopanib: therapeutic developments.

@article{Limvorasak2009PazopanibTD,
  title={Pazopanib: therapeutic developments.},
  author={Suwicha Limvorasak and Edwin M. Posadas},
  journal={Expert opinion on pharmacotherapy},
  year={2009},
  volume={10 18},
  pages={3091-102}
}
Pazopanib (Votrient, GW786034) is a potent pan-VEGF inhibitor in advanced clinical development. Like other orally available VEGFR inhibitors, pazopanib is clinically efficacious and well tolerated. The recently reported Phase III clinical trial in metastatic renal cell carcinoma showed activity similar to approved agents with variations in toxicity which has led to its recent FDA approval. Given the growing number of agents in this category, differences not only in single-agent activity but… CONTINUE READING
Highly Cited
This paper has 19 citations. REVIEW CITATIONS